Michael Morrissey, Exelixis CEO

Ex­elix­is shells out $100M cash in a pair of deals, shoot­ing for dif­fer­ent takes on CD47, AD­Cs

Now that its cabozan­ti­nib fran­chise — in­clud­ing Cabome­tyx tablets and Cometriq cap­sules — has nes­tled its way in­to block­buster sta­tus, Ex­elix­is is re­plen­ish­ing the pipeline with some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.